Evidence map›Paper›PMID 39119466›Full record

ArticleFrontiers in nutrition2024

A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of

Ying Wu, Zhouya Bai, Yuehong Jin, Hong Zhu, Yao Dong, Shaobin Gu, Ying Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Nutrients · 2025
    Article
  3. Foods (Basel, Switzerland) · 2025
    Article
  4. Effect ofFrontiers in nutrition · 2025
    Article
  5. Article
  6. Article
  7. Frontiers in microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying Wu *College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Zhouya Bai *College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Yuehong JinDepartment of Gastroenterology, Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China.
Hong ZhuDepartment of Gastroenterology, Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China.
Yao DongStem Cell Research and Translation Center, Nanjing Agricultural University, Nanjing, China.
Shaobin GuCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Ying JinDepartment of Gastroenterology, Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: This study investigates the role of BC99 in alleviating chronic constipation in a double-blind, placebo-controlled, randomized trial, and participants were divided into BC99 (2 billion CFU/d) or placebo (maltodextrin) groups for a 4-week period. Results and discussion: Results showed that significant improvements were noted in the BC99 group, with an increase in complete spontaneous bowel movements (CSBM) after 4-week treatment compared to the placebo ( Clinical trial registration: ChiCTR2200065493.

Indexed as

chronic constipationgastrointestinal healthprobiotic therapyrandomized controlled trialWeizmannia coagulans BC99

Identifiers

PMID39119466
PMCPMC11306189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.